Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14445760 | 0.88 | POLB (0.54) | POLBSMN1; SMN2ALDH1A1ACACBKMT2A | |
| SCHEMBL19402736 | 0.87 | FAAH (0.49) | POLBSMN1; SMN2ALDH1A1ACACBKMT2A | |
| SCHEMBL25297216 | 0.83 | APAF1 (0.53) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL25831273 | 0.83 | APAF1 (0.53) | SMN1; SMN2ALDH1A1KMT2AMEN1LMNA | |
| SCHEMBL28615671 | 0.82 | CA1 (0.61) | POLBALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL19402738 | 0.82 | CA1 (0.61) | POLBALDH1A1KMT2AMEN1CA1 | |
| SCHEMBL158656 | 0.81 | POLB (0.57) | POLBALDH1A1ACACBKMT2AMEN1 | |
| SCHEMBL13749512 | 0.81 | POLB (0.57) | POLBALDH1A1ACACBKMT2AMEN1 | |
| SCHEMBL24629686 | 0.79 | POLB (0.43) | POLBALOX15SMN1; SMN2ALDH1A1ACACB | |
| SCHEMBL16509661 | 0.78 | ALOX15 (0.55) | ALOX15ALDH1A1KMT2AMEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6784167-B2 | TREATING OSTEOPOROSIS, OSTEOPENIA, OVARIAN CANCER, BREAST CANCER, ENDOMETRIAL CANCER, ENDOMETRIOSIS, PROSTATE CANCER, ACNE, ANDROGEN-DEPENDENT HAIR LOSS, NON-INSULIN-DEPENDENT DIABETES MELLITUS, OR HYPERCHOLESTEROLEMIA. | BAYER PHARMACEUTICALS CORPORATION | 2004-08-31 | — | — | US | disclosed |
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087952-A1 | 17-Beta-hydroxysteroid dehydrogenase-II inhibitors | HSD3B1, HSD3B2, HSD17B1 | POLB 692/4885ALOX15 894/4885SMN1; SMN2 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.